Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact ...

The Portnoy Law Firm advises Hims & Hers Health, Inc. ("Hims & Hers Health" or the "Company") (NYSE: HIMS) investors of a class action representing investors that bought securities between April 29, ...

TheStreet. Telemedicine company GoodRx (GDRX) has been helping Americans find the cheapest way to buy drugs for years. Thanks ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

Shares of Hims & Hers (HIMS) are down 92c, or 2%, to $45.09 in pre-market trading after GoodRx (GDRX) announced that all strengths of Ozempic and Wegovy pens are available to eligible self-paying ...

Truist lowered the firm’s price target on Hims & Hers to $37 from $48 and keeps a Hold rating on the shares. The firm’s intra-quarter Truist Card ...

Ten large-cap stocks, including CRWV, COHR & AMZN, were the worst performers last week. Weak results, downgrades, and FTC ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

Recent health-related developments include Britain's decisions on the bioethanol industry, Berkshire Hathaway's new stake in ...

U.S. equities were mixed at midday following the release of the July retail sales report, which came in as expected.

The disclosure in a filing Thursday gave a much-needed boost to the beleaguered health insurance giant, which saw shares jump as much as 9.6% in post-market trading. In other news: Nike co-founder ...